What Are Common Reasons for Supplemental Information Requests in IVD Overseas Registration?

Common reasons for supplemental information requests in IVD overseas registration include product classification errors, incomplete technical documentation, insufficient clinical evidence, non-compliant labeling and instructions for use, mismatched quality management system (QMS) documents, missing authorized representative or local agent information, and unclear post-market surveillance plans. To minimize deficiency risks, companies should first determine whether their product falls under the medical device regulatory scope of the target country, then identify the correct registration pathway based on risk classification. Existing NMPA, CE, or FDA documentation can be leveraged but must be localized for markets such as GHWP member states, Southeast Asia, the Middle East, and Latin America.

Application Scenarios and Core Issues

During overseas IVD registration, deficiency letters are common regulatory feedback. They typically indicate that submitted materials do not fully meet the requirements of the target country or region. Core issues stem from insufficient understanding of local medical device regulations, especially for IVD-specific requirements such as classification rules, performance evaluation, clinical evidence, and QMS documentation. For example, the European IVDR (EU 2017/746) significantly raises requirements for IVD classification, clinical performance, and safety, while countries like Thailand and Indonesia maintain their own registration pathways and document lists. Deficiencies not only prolong approval timelines but also increase costs.

Registration Decision Logic

Before initiating overseas registration, companies should follow a clear decision logic:

• Determine whether the product falls under the target country's medical device regulatory scope. For instance, Saudi Arabia and Brazil have clear IVD definitions, but some rapid test kits may fall under drug or food regulations.
• Identify the product's risk classification. Countries classify IVDs from low to high risk, e.g., classes A–D under EU IVDR or classes I–III under US FDA. Misclassifying a higher-risk product as lower-risk will inevitably trigger a deficiency.
• Select the correct registration pathway: EU requires notified body review, US requires 510(k) or PMA, while many Southeast Asian countries adopt notification or simplified registration. Choosing the wrong pathway leads to deficiencies.
• Assess the reusability of existing technical files. Documents from NMPA, CE, or FDA approvals can save time, but local epidemiological data, population-specific clinical samples, and language conversion may be necessary.
• Confirm whether QMS certificates (e.g., ISO 13485, MDSAP) are recognized by the target country. For example, Brazil's ANVISA recognizes MDSAP, but Indonesia does not.
• Ensure that the local agent or authorized representative's qualification documents are valid and that the post-market surveillance plan is complete.

Required Documentation and Evidence

Registration dossiers typically include these core documents, where deficiencies are most common:

• Product Technical File: Must include product description, intended use, design principles, raw materials, and manufacturing process. Missing key parameters or unclear descriptions are common triggers.
• Performance Evaluation Report: Analytical performance (sensitivity, specificity, precision, limit of detection, etc.) and stability data must conform to local guidelines (e.g., CLSI or ISO 15189). Insufficient data or improper study design are frequent deficiency reasons.
• Clinical Evidence: Clinical evaluation reports should be based on thorough literature reviews or clinical trial data. For high-risk IVDs, local clinical data are often mandatory. Deficiencies arise when evidence is inadequate or not representative of the local population.
• Labels and Instructions for Use: Must be provided in the official language and comply with local content requirements. For example, EU IVDR requires labels to include CE marking, IFU language, storage conditions, etc. Missing any item results in a deficiency.
• QMS Documents: ISO 13485 or MDSAP certificates must be valid and cover the target product. Expired certificates or scopes that do not include the product will also trigger deficiencies.
• Authorized Representative Documents: Most countries require a local agent and a valid power of attorney with local qualification proof. Incomplete or expired documents are common deficiency causes.

Common Errors

• Product classification errors: Incorrectly classifying products according to local rules, e.g., submitting a self-test IVD under IVDD classification when IVDR applies.
• Incomplete performance data: Missing key performance indicators (e.g., inter-batch variation, cross-reactivity) or using inappropriate statistical methods.
• Insufficient clinical evaluation: Inadequate literature search strategies, lack of local population data, or direct use of foreign data without demonstrating comparability.
• Non-compliant labeling: Not using the official language or missing required information (e.g., warnings, storage conditions, expiry date).
• QMS certificate issues: Expired certificates, products not covered under the scope, or certificates not recognized by the target country.
• Incorrect local agent information: Improperly signed authorization documents or agents lacking local business licenses.
• Missing post-market surveillance plan: Failure to submit Post-Market Performance Follow-up (PMPF) or adverse event reporting documents.

Preparation Checklist

• Confirm the target country's regulatory framework and product classification rules.
• Identify gaps in existing technical files and create a supplementary plan.
• Complete performance verification (analytical performance, stability, clinical studies).
• Draft clinical evaluation reports or design clinical trial protocols.
• Translate and adapt labels and IFUs to local requirements.
• Update QMS certificates to ensure coverage of target products.
• Sign and notarize local agent or authorized representative agreements.
• Draft post-market surveillance plans, including PMPF and PSUR.
• Conduct a mock submission audit against local guidelines.

AIMEILI Regulatory Interpretation and Business Impact

In IVD overseas registration, the most common misjudgments involve product classification and sufficiency of clinical evidence. We recommend that companies begin with a thorough regulatory background investigation to confirm classification and registration pathway, as errors here render all subsequent efforts futile. Many companies assume that existing NMPA or CE documentation can be directly reused, overlooking local requirements for performance or clinical data—for instance, Brazil requires local clinical samples, while Middle Eastern countries tend to accept FDA data. Reusable core technical files include product descriptions, design documentation, risk management reports (ISO 14971), and key performance parameters, but localization is essential, especially for language, standard references, and epidemiological data.

Regarding local agents, companies often neglect the issue of control. Agents require long-term cooperation; changes or expired qualifications can lead to suspension of registration certificates. For multi-country registrations, we recommend establishing a unified document platform managed by regulatory personnel, extracting relevant modules for each market and adapting them accordingly to reduce repetitive work and deficiency risks. Certificate control is equally important—some countries issue registration certificates only to local agents, so companies must contractually ensure timely updates and renewals. Finally, post-market maintenance is not an afterthought but an integral part of the registration dossier; missing this can result in deficiencies or even rejection.

Frequently Asked Questions

How long does it typically take to respond to a deficiency notice for IVD products?

Response deadlines vary by country. For example, under EU IVDR, the response period is typically 90 days, but extensions may be requested. Southeast Asian countries like Malaysia and Indonesia allow 30–60 days. Companies should plan ahead to avoid expiration of the application.

Do deficiency rates differ significantly between countries?

Yes. Industry experience shows that the deficiency rate for EU IVDR exceeds 80% due to strict new regulations; US FDA 510(k) deficiency rate is about 50%, mainly for performance data and clinical evidence; Southeast Asian countries like Thailand and the Philippines have lower deficiency rates (around 30%) due to simpler documentation requirements, though requirements have become stricter recently.

How can companies effectively reduce the risk of deficiency?

We recommend using a pre-review mechanism: before formal submission, have an internal regulatory team or third-party consultant conduct a mock audit of the full dossier against the target country's latest guidelines. Additionally, establish a template library for registration documents to ensure consistency. Early communication with regulatory bodies (e.g., FDA Q-submission) can also reduce later deficiencies.

Based on AIMEILI registration practice database, medical device international registration knowledge base, and publicly available regulatory information. Published: 2026-07-29. Updated: 2026-07-29. For specific projects, refer to the latest requirements of the target country's regulatory authority and the product-specific dossier.